KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for Inovio Pharmaceuticals (INO) over the last 17 years, with Q3 2025 value amounting to $69.8 million.

  • Inovio Pharmaceuticals' Total Current Liabilities rose 19713.39% to $69.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $69.8 million, marking a year-over-year increase of 19713.39%. This contributed to the annual value of $35.3 million for FY2024, which is 1701.81% down from last year.
  • As of Q3 2025, Inovio Pharmaceuticals' Total Current Liabilities stood at $69.8 million, which was up 19713.39% from $31.7 million recorded in Q2 2025.
  • Inovio Pharmaceuticals' Total Current Liabilities' 5-year high stood at $131.1 million during Q2 2022, with a 5-year trough of $23.4 million in Q1 2024.
  • For the 5-year period, Inovio Pharmaceuticals' Total Current Liabilities averaged around $53.9 million, with its median value being $51.4 million (2021).
  • Per our database at Business Quant, Inovio Pharmaceuticals' Total Current Liabilities plummeted by 6037.64% in 2023 and then surged by 19713.39% in 2025.
  • Over the past 5 years, Inovio Pharmaceuticals' Total Current Liabilities (Quarter) stood at $65.7 million in 2021, then skyrocketed by 47.35% to $96.9 million in 2022, then plummeted by 56.05% to $42.6 million in 2023, then fell by 17.02% to $35.3 million in 2024, then soared by 97.66% to $69.8 million in 2025.
  • Its Total Current Liabilities stands at $69.8 million for Q3 2025, versus $31.7 million for Q2 2025 and $27.3 million for Q1 2025.